Theratechnologies Inc. Files Form 6-K
| Field | Detail |
|---|---|
| Company | Theratechnologies Inc. |
| Form Type | 6-K |
| Filed Date | Aug 18, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release
TL;DR
Theratechnologies filed a 6-K on Aug 18, 2025, likely with a press release attached. Check for updates.
AI Summary
Theratechnologies Inc. filed a Form 6-K on August 18, 2025, to report a press release dated August 18, 2025. The filing does not contain specific financial figures or operational updates beyond the announcement of the press release itself.
Why It Matters
This filing indicates Theratechnologies Inc. is providing an update to the market, likely through the attached press release, which could contain material information for investors.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to attach a press release, with no immediate indication of significant new risks or opportunities presented within the filing itself.
Key Players & Entities
- Theratechnologies Inc. (company) — Filer of the Form 6-K
- August 18, 2025 (date) — Date of the press release and filing
- Jocelyn Lafond (person) — General Counsel and Corporate Secretary who signed the filing
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report a press release dated August 18, 2025, as required for foreign private issuers.
What is the filing date of this Form 6-K?
The Form 6-K was filed on August 18, 2025.
Who is the filer of this report?
The filer of this report is Theratechnologies Inc.
What is the principal executive office address of Theratechnologies Inc.?
The principal executive office address is 2015 Peel Street, Suite 1100, Montreal, Quebec H3A 1T8, Canada.
What exhibit is included with this Form 6-K?
Exhibit 99.1, a Press Release Dated August 18, 2025, is included with this Form 6-K.
Filing Stats: 151 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2025-08-18 07:52:04
Filing Documents
- d67180d6k.htm (6-K) — 8KB
- d67180dex991.htm (EX-99.1) — 33KB
- g67180g0817175407698.jpg (GRAPHIC) — 3KB
- 0001193125-25-182217.txt ( ) — 46KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. THERATECHNOLOGIES INC. By: /s/ Jocelyn Lafond Name: Jocelyn Lafond Title: General Counsel and Corporate Secretary Date: August 18, 2025